— AR882 demonstrated safe and efficacious long-term reduction of serum urate (sUA) levels and elimination of urate crystal deposition in a sub-analysis of gout patients from the Asia-Pacific region— SAN DIEGO, Calif. , Aug. 23, 2024 /PRNewswire/ -- Arthrosi Therapeutics, Inc.
, a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and tophi in patients with gout, today announced additional positive data from a sub-population analysis for its Phase 2 clinical program in gout patients from the Asia-Pacific region. These data are being presented as a poster at the 26 th Asia-Pacific League of Associations for Rheumatology Congress, being held August 21-25 in Suntec, Singapore . "We are excited to present new sub-population data from our previously reported positive Phase 2 clinical program for AR882 at APLAR as there remains a significant unmet need for patients suffering from gout worldwide," said Robert T.
Keenan , MD, MPH, MBA, Chief Medical Officer at Arthrosi Therapeutics. "The data to be showcased further reinforces AR882's potential to drive robust, durable sUA and tophi reduction, while achieving an improved safety profile compared to existing standard of care to date. Most notably, 83% of patients who received 75mg of AR882 achieved serum urate levels below 5 mg/dL, which is essential for resolving debilitating tophi, crystal burden and flares.
We loo.